Penicillin Use in Meningococcal Disease Management: Active Bacterial Core Surveillance Sites, 2009.

• Type of Material: Article
• Authors: Amy E. Blain, Centers for Disease Control and Prevention; Sema Mandal, Centers for Disease Control and Prevention; Henry Wu, Centers for Disease Control and Prevention; Jessica R. MacNeil, Centers for Disease Control and Prevention; Lee H. Harrison, Johns Hopkins University; Monica Farley, Emory University; Ruth Lynfield, Minnesota Department of Health; Lisa Miller, Colorado Department of Public Health and Environment; Megin Nichols, New Mexico Department of Health; Sue Petit, Connecticut Department of Public Health; Arthur Reingold, University of California, Berkeley; William Schaffner, Vanderbilt University; Ann Thomas, Oregon Department of Human Services; Shelley M. Zansky, New York State Department of Health; Raydel Anderson, Centers for Disease Control and Prevention; Brian H. Harcourt, Centers for Disease Control and Prevention; Leonard Mayer, Emory University; Thomas A. Clark, Centers for Disease Control and Prevention; Amanda C. Cohn, Centers for Disease Control and Prevention
• Language: English
• Date: 2016-09
• Publisher: Oxford University Press (OUP)
• Publication Version: Final Published Version
• Copyright Statement: Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofw152
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• ISSN: 2328-8957
• Volume: 3
• Issue: 3
• Start Page: ofw152
• End Page: ofw152
• Keywords: Neisseria meningitidis; antimicrobial resistance; meningococcal disease; meningitis
• Research Categories: Health Sciences, Epidemiology; Health Sciences, Public Health

Abstract

In 2009, in the Active Bacterial Core surveillance sites, penicillin was not commonly used to treat meningococcal disease. This is likely because of inconsistent availability of antimicrobial susceptibility testing and ease of use of third-generation cephalosporins. Consideration of current practices may inform future meningococcal disease management guidelines.